Factor XIa Inhibition : Is It a Novel Alternative Antithrombotic Strategy for High-Risk ACS Patients?
| Errataetall: |
CommentOn: Circulation. 2022 Oct 18;146(16):1196-1206. - PMID 36030390 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:146 |
|---|---|
| Enthalten in: |
Circulation - 146(2022), 16 vom: 18. Okt., Seite 1207-1209 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Gue, Ying X [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Acute coronary syndrome |
|---|
| Anmerkungen: |
Date Completed 19.10.2022 Date Revised 22.01.2023 published: Print-Electronic CommentOn: Circulation. 2022 Oct 18;146(16):1196-1206. - PMID 36030390 Citation Status MEDLINE |
|---|
| doi: |
10.1161/CIRCULATIONAHA.122.061987 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM345478304 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM345478304 | ||
| 003 | DE-627 | ||
| 005 | 20231226025139.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1161/CIRCULATIONAHA.122.061987 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1151.xml |
| 035 | |a (DE-627)NLM345478304 | ||
| 035 | |a (NLM)36030388 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Gue, Ying X |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Factor XIa Inhibition |b Is It a Novel Alternative Antithrombotic Strategy for High-Risk ACS Patients? |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 19.10.2022 | ||
| 500 | |a Date Revised 22.01.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a CommentOn: Circulation. 2022 Oct 18;146(16):1196-1206. - PMID 36030390 | ||
| 500 | |a Citation Status MEDLINE | ||
| 650 | 4 | |a Editorial | |
| 650 | 4 | |a Comment | |
| 650 | 4 | |a Editorials | |
| 650 | 4 | |a acute coronary syndrome | |
| 650 | 4 | |a factor XIa | |
| 650 | 4 | |a hemorrhage | |
| 650 | 7 | |a Anticoagulants |2 NLM | |
| 650 | 7 | |a Fibrinolytic Agents |2 NLM | |
| 650 | 7 | |a Platelet Aggregation Inhibitors |2 NLM | |
| 650 | 7 | |a Factor XIa |2 NLM | |
| 650 | 7 | |a EC 3.4.21.27 |2 NLM | |
| 700 | 1 | |a Gorog, Diana A |e verfasserin |4 aut | |
| 700 | 1 | |a Lip, Gregory Y H |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Circulation |d 1950 |g 146(2022), 16 vom: 18. Okt., Seite 1207-1209 |w (DE-627)NLM000039020 |x 1524-4539 |7 nnns |
| 773 | 1 | 8 | |g volume:146 |g year:2022 |g number:16 |g day:18 |g month:10 |g pages:1207-1209 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1161/CIRCULATIONAHA.122.061987 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 146 |j 2022 |e 16 |b 18 |c 10 |h 1207-1209 | ||